论文部分内容阅读
目的 :通过采用胃肠起搏器和吗丁啉药物的对比治疗 ,观察亚高原地区功能性消化不良 (functionaldyspepsia,FD)的临床疗效 ,并选择出胃肠起搏器治疗亚高原地区的FD的最佳频率和时间等指标 ;方法 :临床随机选择病例 ,分为胃肠起搏器治疗组和吗丁啉药物治疗对照组 ,同时记录治疗前后临床症状变化情况和胃电图检查中的平均频率及平均幅值 ;结果 :两组患者经不同方法治疗后 ,对照组治疗前后临床症状变化不大 ,P >0 .0 5,而治疗组治疗后临床症状除呕吐外 ,其它症状治疗前后均有显著改善P <0 .0 1 ;治疗前后胃电频率改变 ,治疗组餐前及餐后的平均胃电频率明显趋向正常频率 (3 .0次 /秒 ) ,经自身对照的t检验统计P <0 .0 5;而对照组经t检验无统计学意义 ,两组治疗前后胃电幅度值经t检验均无统计学意义 ;结论 :在体表输入一个较佳的治疗参数 ,能显著改善亚高原地区FD患者的胃运动功能和临床症状 ,胃肠起搏器对治疗亚高原地区FD疾病的治疗具有一定的临床价值 ,值得临床进一步研究
OBJECTIVE: To observe the clinical efficacy of functional dyspepsia (FD) in the sub-plateau by comparing the gastrointestinal pacemaker with domperidone, and to select the gastrointestinal pacemaker for the treatment of FD in the sub-plateau The best frequency and the best time and other indicators; Methods: Randomly selected clinical cases, divided into gastrointestinal pacemaker treatment group and domperidone drug treatment control group, meanwhile record the changes of clinical symptoms before and after treatment and the average frequency of gastric electrogastrogram And the average amplitude; Results: After the two groups of patients by different methods of treatment, the clinical symptoms before and after treatment in the control group changed little, P> 0.05, while the treatment group after treatment of symptoms except vomit, other symptoms before and after treatment Significantly improved P <0.01; before and after treatment of gastric electrical frequency changes, the treatment group before and after meal, the average frequency of gastric electrification tends to normal frequency (3.0 times / sec), by their own control t test statistics P < 0 .0 5; while the control group by t test was not statistically significant, the two groups before and after treatment of gastric electrical amplitude values by t test were not statistically significant; Conclusion: In the body surface to enter a better treatment parameters, can significantly improve the sub-Asian FD patients in the plateau Gastric motor function and clinical symptoms, gastrointestinal pacemaker for the treatment of sub-plateau FD disease has some clinical value, it is worth further clinical study